CSBio CSBio

X
[{"orgOrder":0,"company":"Laboratori Derivati Organici","sponsor":"Cerus DMCC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CERUS Announces the Acquisition of Laboratori Derivati Organici SpA (LDO) by Opocrin SpA","therapeuticArea":"Hematology","highestDevelopmentStatus":"Undisclosed","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"April 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Laboratori Derivati Organici"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Transaction enables Opocrin to become a leading global producer of active biologics including heparin and heparinoids.

            Lead Product(s): Heparin Sodium

            Therapeutic Area: Hematology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Cerus DMCC

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition April 29, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY